Fleury S.A. (BVMF:FLRY3)

Market Cap	9.81B +27.9%
Revenue (ttm)	8.79B +12.1%
Net Income	704.31M +16.2%
EPS	n/a
Shares Out	543.62M
PE Ratio	13.93
Forward PE	12.13
Dividend	1.21 (6.70%)
Ex-Dividend Date	Aug 12, 2026

Volume	n/a
Open	18.25
Previous Close	18.05
Day's Range	18.20 - 18.46
52-Week Range	13.78 - 19.73
Beta	0.21
Analysts	Hold
Price Target	17.63 (-3.56%)
Earnings Date	Aug 6, 2026

About Fleury

Fleury S.A., together with its subsidiaries, engages in the provision of diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides medical services in the areas of diagnostics, laboratory support, infusions, clinical analyses, health management, healthcare, assistance medicine, orthopedics, ophthalmology, toxicological tests, fertility, infusions, and others. In addition, it operates a health platform, immunobiological d...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1926
• Employees: 29,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: FLRY3

Financial Performance

In 2025, Fleury's revenue was 8.29 billion, an increase of 7.89% compared to the previous year's 7.68 billion. Earnings were 612.83 million, a decrease of -0.54%.

Analyst Summary

According to 12 analysts, the average rating for FLRY3 stock is "Hold." The 12-month stock price target is R$17.63, which is a decrease of -3.56% from the latest price.

Price Target

R$17.63

(-3.56% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 19, 2026

Data Sources Report a data error